DuoPlavin/DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). It is a fixed dose combination medicinal product for continuation of therapy in non-ST segment elevation acute coronary syndrome including patients undergoing a stent placement following percutaneous coronary intervention.
DuoPlavin/DuoCover is also indicated for the treatment of ST-segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.
Both the parties said that the new formulation of DuoPlavin/DuoCover carrying both these antiplatelets in one single tablet contributes to reducing daily pill burden for patients.